澳大利亚维多利亚州验尸官David Ryan于周三发布调查结果，建议在著名演员Richard Norton因注射未获批准肽类物质导致心脏骤停死亡后，由澳大利亚治疗用品管理局（TGA）对CJC1295和ipamorelin等物质的处方权限进行审查1。验尸官指出，目前证据不足以支持医生开具此类药物，并建议将其从第四级处方药（Schedule 4）调整为第十级（Schedule 10），即仅限临床试验或实验性使用1。
死者Richard Norton是一名75岁的澳大利亚演员、特技协调员及武术家，他于2025年3月19日获得上述肽类注射剂的处方1。在3月28日向护士透露其自行注射了双倍剂量药物后，Norton于3月30日在Alfred医院去世，死因为心脏骤停1。验尸官强调：“我不满意这些药物被允许由医疗从业者开出处方”，专家结论也显示缺乏证据证明CJC1295或Ipamorelin对人类安全、有效或有益1。
涉事医生Jerzy Muchnicki被澳洲医学委员会独立专家认定为记录“稀疏、不充分且敷衍”，低于合理预期标准1。尽管认定该医生存在违规，医学委员会认为无需对其实施监管处罚，但要求其接受一对一的临床记录和管理培训1。
A Victorian coroner has recommended that Australia’s Therapeutic Goods Administration (TGA) reassess the safety and efficacy of unapproved peptide substances after linking their use to the death of renowned actor and stunt coordinator Richard Norton 1. The finding stems from an investigation into Norton’s fatal cardiac arrest in March 2025, which occurred shortly after he administered a double dose of prescription peptides known as CJC1295 and ipamorelin 1. Coroner David Ryan concluded that current evidence is insufficient to support the prescribing of these substances by medical practitioners and proposed reclassifying them from Schedule 4—available only with a prescription—to Schedule 10, restricting their use solely to clinical trials or experimental purposes 1.
Norton, a 75-year-old martial artist and stunt professional, received the initial prescriptions on March 19, 2025 1. Eight days later, on March 28, he disclosed to a nurse that he had self-administered twice the prescribed amount, ultimately dying at Alfred Hospital on March 30 due to cardiac arrest 1. While the treating physician, Jerzy Muchnicki, was found by an independent expert panel of the Australian Medical Board to have maintained "sparse, inadequate, and perfunctory" records that fell below reasonable standards, no regulatory penalties were imposed against him 1. Instead, the board mandated one-on-one training for Muchnicki regarding clinical documentation and management practices 1.
In his findings released on Wednesday, Coroner Ryan stated, "I am not satisfied that it is appropriate for them to be available to be prescribed by medical practitioners," reflecting the broader conclusion that there is "insufficient evidence that CJC1295 or Ipamorelin is safe, effective or beneficial for human use" 1.
评论
还没有评论，欢迎留下第一条。